

COVID-19 Vaccine Update

Webinar 6

Date: April 26th, 2023

Presentation By:

Allie Staton, PharmD

Vaccine Confidence Strategist

Immunize Arkansas

Email: allie@immunizear.org



UAMS DISCLOSURE POLICY

It is the policy of the University of Arkansas for Medical Sciences (UAMS) to ensure balance, independence, objectivity, and scientific rigor in all directly or jointly provided educational activities.

All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. The ACCME and ACPE describe relevant financial relationships as those in any amount occurring within the past 24 months that create a conflict of interest. *Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CE activity.*

DISCLOSURES

The following planners and speakers of this CE activity have no relevant financial relationships with ineligible companies to disclose:

Allie Staton, PharmD

The accreditation compliance reviewers, Courtney Bryant and Sara Hale, have no relevant financial relationships with ineligible companies to disclose.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



CREDIT DESIGNATION STATEMENTS

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CONTINUING EDUCATION

To receive Continuing Education:

- **You must attend this webinar as it is being presented.**
 - Attendance will be recorded via Zoom to determine if you were present.
 - If you are watching this as a recording, you will not be eligible to receive CE.
- **You must complete the Evaluation Survey following this webinar.**
 - A link to the Evaluation Survey will be posted in the chat at the end of the presentation.
 - **DEADLINE: Midnight on Thursday, April 27th**
 - **No late evaluations will be accepted.** Please complete the survey ASAP.
 - The survey link will also be sent out tomorrow afternoon in a follow-up email.
- **Certificates of Completion for attending this course will be available after you complete the Evaluation Survey.**
 - After you complete the survey, you will be directed to Certificates of Completion website.
 - You will have to write your name on the Certificate.
 - A link to the Certificates of Completion will also be sent out tomorrow afternoon in a follow-up email.

WEBINAR

- If you have a question during or after the webinar, please post your question in the chat.
 - We will do our best to answer all questions before the end of the webinar.
- If you have a question after the webinar, please email Allie Staton.
 - allie@immunizear.org

OBJECTIVES

At the end of this webinar, learners will be able to:

- Interpret current COVID-19 vaccine guidelines.
- Recommend appropriate vaccines to patients and community members.
- Discuss current COVID-19 vaccine guidelines and recommendations.

TOPICS

- Review updated COVID-19 vaccine recommendations
- Discuss commonly asked questions

CDC INTERIM CLINICAL CONSIDERATIONS FOR COVID-19 VACCINES

COVID-19 vaccine recommendations are based on:

- Age
- Health Status
 - Healthy versus Immunocompromised
- Previous doses of COVID-19 vaccines

Recommendations for use of COVID-19 vaccines are published on the CDC's website.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>


CURRENTLY AVAILABLE PRODUCTS

COVID-19 VACCINE PRODUCT REVIEW

Pfizer	Moderna	Janssen / J&J	Novavax
mRNA	mRNA	Adenovirus Vector	Protein Subunit
6 months and older	6 months and older	18 years and older	12 years and older
<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older 	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 months and older 	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 18 years and older 	<p><u>Products</u> Monovalent:</p> <ul style="list-style-type: none"> - 12 years and older

PFIZER / BIONTECH

	Pfizer Monovalent			Pfizer Bivalent		
	Pfizer Primary Series	Pfizer Primary Series	Pfizer Primary Series	Pfizer Bivalent Primary Series (3 rd dose only)	Pfizer Bivalent Booster	Pfizer Bivalent Booster
Age Group	6 months thru 4 years	5 years thru 11 years	12 years and older	6 months thru 4 years	5 years thru 11 years	12 years and older
Vial Cap and Label color	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray
Dilution?	YES (2.2 mL)	YES (2.2 mL)	NO	YES (2.2 mL)	YES (1.3 mL)	NO
Dose Volume	0.2 mL	0.2 mL	0.3 mL	0.2 mL	0.2 mL	0.3 mL
Doses per Vial	10	10	6	10	10	6
Expiration	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours



Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.


PFIZER / BIONTECH

	Pfizer Bivalent		
	Pfizer Bivalent	Pfizer Bivalent	Pfizer Bivalent
Age Group	6 months thru 4 years	5 years thru 11 years	12 years and older
Vial Cap and Label color	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray
Dilution?	YES (2.2 mL)	YES (1.3 mL)	NO
Dose Volume	0.2 mL	0.2 mL	0.3 mL
Doses per Vial	10	10	1 or 6
Expiration	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours

Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

MODERNA

	Moderna Monovalent			Moderna Bivalent	
	Moderna Primary Series	Moderna Primary Series	Moderna Primary Series	Moderna Bivalent Booster	Moderna Bivalent Booster
Age Group	6 months thru 5 years	6 years thru 11 years	12 years and older	6 months thru 5 years	6 years and older
Vial Cap and Label color	Cap: Blue Label Border: Magenta	Cap: Blue Label Border: Magenta	Cap: Red Label Border: Blue	Cap: Dark Pink Label Border: Yellow	Cap: Blue Label Border: Gray
Dilution?	NO	NO	NO	NO	NO
Dose Volume	0.25 mL	0.25 mL	0.5 mL	0.2 mL	6 – 11 years: 0.25 mL 12 years and older: 0.5 mL
Doses per Vial	10	5	11	2	5
Expiration	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 8 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours



Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

MODERNA

	Moderna Bivalent	
	Moderna Bivalent	Moderna Bivalent
Age Group	6 months thru 5 years	6 months and older
Vial Cap and Label color	Cap: Dark Pink Label Border: Yellow	Cap: Blue Label Border: Gray
Dilution?	NO	NO
Dose Volume	0.2 mL	6 months – 11 years: 0.25 mL 12 years and older: 0.5 mL
Doses per Vial	2	5 to 10 (depends on dose volume)
Expiration	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 8 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours

The cartons and labels for both of these products say “**BOOSTER DOSES ONLY**”.

Ignore that...

Always follow EUAs instead of labels on products for COVID-19 vaccines.

DISPOSAL OF MONOVALENT mRNA VACCINES

Removal of monovalent mRNA COVID-19 Vaccine from Inventory:

To minimize the risk of administration error with de-authorized monovalent mRNA vaccine, COVID-19 vaccine providers should:

- Remove and dispose of all monovalent mRNA vaccine from your **storage units** immediately, even if they are not expired. This includes both EUA and BLA products (Comirnaty and Spikevax)
- Disposal of **all monovalent mRNA COVID-19 vaccine vials** should be in a medical waste container.
- Remove the monovalent mRNA COVID-19 vaccine in your WebIZ inventory.
 - Please choose "Removing – Recall" as the Reason for disposal.
 - Adjust the inventory appropriately so that it shows zero doses for all monovalent products.

For questions regarding disposal and WebIZ, please contact Seavia Dixon at Arkansas Department of Health.
Email: seavia.dixon@arkansas.gov

JANSSEN / JOHNSON & JOHNSON

	J&J Primary Series
Age Group	18 years and older
Dilution?	NO
Dose Volume	0.5 mL
Doses per Vial	5
Expiration	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: 12 hours After Puncture: 6 hours in fridge, or 2 hours at room temp

J&J should only be used in certain situations.

Pfizer, Moderna, and Novavax are all preferred over J&J.

WARNING: Thrombosis with Thrombocytopenia Syndrome

- COVID-19 vaccine providers must counsel on this risk before administration of J&J.
- See EUA for more information.



NOVAVAX

	Novavax Primary Series	Novavax Booster Dose (same product as primary series)
Age Group	12 years and older	18 years and older
Dilution?	NO	NO
Dose Volume	0.5 mL	0.5 mL
Doses per Vial	10	10
Expiration	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp

Novavax has a mechanism that is similar to vaccines that have been approved for years.

This vaccine is an option for those who are hesitant about the mRNA technology that was used for the other COVID-19 vaccines.

**See next slide for Booster
Dose Eligibility**

Use of the monovalent Novavax booster dose in limited situations

- People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine **and have not received any previous booster dose(s)** may receive a monovalent Novavax booster dose **at least 6 months after completion of the primary series** if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Novavax Booster Eligibility:

- 18 years or older
- Completed primary series of a monovalent product
- 6 months since last dose of primary series
- No booster doses of an mRNA product
- Unable or unwilling to receive an mRNA bivalent booster

CURRENT RECOMMENDATIONS
(HEALTHY)

Use of COVID-19 Vaccines in the United States

Interim Clinical Considerations

Summary of recent changes (last updated April 22, 2023):

- Revision of the mRNA COVID-19 vaccination schedule as follows:
 - At the time of initial vaccination, depending on vaccine product, children ages 6 months–4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses; children age 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses
 - People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose
 - People ages 65 years and older may receive 1 additional bivalent mRNA vaccine dose

NOT YET UPDATED: Clinical Considerations for patients moderately to severely immunocompromised.

UPDATES – AGES 6 YEARS AND OLDER

- Monovalent mRNA vaccines no longer authorized for use.
- Everyone ages 6 months and older is eligible for at least one dose of bivalent mRNA vaccine.
 - Most people who have already received one dose of a bivalent mRNA vaccine are not eligible for another dose of bivalent.
- People ages 65 and older are eligible for a second dose of a bivalent mRNA vaccine.
 - Must be at least 4 months after first dose of bivalent.
- Immunocompromised people ages 6 years and older are eligible for a second dose of a bivalent mRNA vaccine.
 - Must be at least 2 months after first dose of bivalent.
- Unvaccinated people ages 6 years and older may receive one dose of a bivalent mRNA vaccine.
 - This is considered a complete primary series.
- If someone ages 6 years and older received one dose of a monovalent mRNA vaccine...
 - Must wait 8 weeks, then eligible to receive one dose of a bivalent mRNA vaccine to complete their primary series.

UPDATES – AGES 6 MONTHS THRU 5 YEARS

- Monovalent mRNA vaccines no longer authorized for use.
- Children ages 6 months thru 5 years who are unvaccinated...
 - May receive a 2-dose series of Moderna bivalent OR a 3-dose series of Pfizer bivalent.
- Children ages 6 months thru 5 years who received one, two, or three doses of a monovalent vaccine...
 - May receive a bivalent vaccine, but the number of doses depends on their monovalent vaccination history.

COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

The COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is summarized in [Table 1](#).

The schedule is organized by age and COVID-19 vaccination history. It provides the number of bivalent mRNA vaccine doses an individual needs based on COVID-19 vaccine doses previously received, including the number of prior doses, whether the doses were monovalent or bivalent, and the vaccine manufacturer (Moderna, Novavax, or Pfizer-BioNTech).

Most people ages 6 years and older who are not moderately or severely immunocompromised and have received 1 dose of a bivalent mRNA vaccine do not need any further vaccine doses at this time. People ages 65 years and older who received 1 dose of a bivalent vaccine have the option to receive 1 additional dose at least 4 months after the first bivalent dose.

Table 1. COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised by COVID-19 vaccination history, April 2023

mRNA COVID-19 vaccines

Ages 12 years and older

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses*
Unvaccinated	Moderna ___or___	1	0.5 mL/50 ug	Dark blue cap; gray label border	—
	Pfizer BioNTech	1	0.3 mL/30 ug	Gray	—
1 or more doses monovalent mRNA (no doses bivalent mRNA)	Moderna ___or___	1	0.5 mL/50 ug	Dark blue cap; gray label border	At least 8 weeks after last monovalent dose
	Pfizer BioNTech	1	0.3 mL/30 ug	Gray	At least 8 weeks after last monovalent dose
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine. If Moderna is used, administer 0.5 mL/50 ug (dark blue cap and label with a gray border); if Pfizer-BioNTech is used, administer 0.3 mL/30 ug (gray cap and label with a gray border).

Abbreviation: NA = not authorized

*An [8-week interval](#) between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

COVID-19 Vaccine Recommendations

Healthy Adults: Administration of Primary Series and Booster Doses (ages 18 and older)

Date: April 19, 2023



PRIMARY SERIES			ADDITIONAL DOSES	
	Dose 1		Booster	
Pfizer Cap: Gray	(primary) Pfizer Bivalent: 0.3 mL		Patients 65 years and older: Wait 4 months →	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	Moderna Cap: Dark Blue Label: Gray	(primary) Moderna Bivalent: 0.5 mL		Patients 65 years and older: Wait 4 months →

	Dose 1		Dose 2	Booster	
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 – 8 weeks →	(primary) Novavax Monovalent: 0.5 mL	Wait 2 months →	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
				OR Wait 6 months*	OR Novavax Monovalent: 0.5 mL

	Dose 1		Booster	
J & J J&J should only be used in limited situations	(primary) J&J Monovalent: 0.5 mL		Wait 2 months →	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
			OR Wait 6 months*	OR Novavax Monovalent: 0.5 mL

*Novavax may only be used as a booster dose in limited situations. Patients must meet ALL of the following criteria to be eligible: 1) 18 years and older 2) completed a primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine, 3) have not received any previous booster dose(s), and 4) are unable (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Please see CDC Interim Clinical Considerations for official guidance.

Use of the monovalent Novavax booster dose in limited situations

- People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine **and have not received any previous booster dose(s)** may receive a monovalent Novavax booster dose **at least 6 months after completion of the primary series** if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Novavax Booster Eligibility:

- 18 years or older
- Completed primary series of a monovalent product
- 6 months since last dose of primary series
- No booster doses of an mRNA product
- Unable or unwilling to receive an mRNA bivalent booster

COVID-19 Vaccine Recommendations

Healthy Adults and Teens: Administration of Primary Series and Booster Doses (ages 12 and older)

Date: April 19, 2023



Ages: 12 years and older						
	COVID-19 Vaccine History					Booster
Pfizer Cap: Gray	Unvaccinated		Pfizer Bivalent: 0.3 mL			Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	1 dose monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.3 mL			
	2 doses monovalent Pfizer	Wait 8 weeks	OR			
	1 or more doses of monovalent Pfizer	Wait 8 weeks	Moderna Bivalent: 0.5 mL			
	1 dose <i>bivalent</i> Pfizer		N/A			
Moderna Cap: Dark Blue Label: Gray	Unvaccinated		Moderna Bivalent: 0.5 mL			Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	1 dose monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.3 mL			
	2 doses monovalent Moderna	Wait 8 weeks	OR			
	1 or more doses of monovalent Moderna	Wait 8 weeks	Moderna Bivalent: 0.5 mL			
	1 dose <i>bivalent</i> Moderna		N/A			
Novavax	Unvaccinated		Novavax Monovalent: 0.5 mL	<i>see next row for guidance after 1 dose of Novavax monovalent</i>		Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	1 dose monovalent Novavax	Wait 3 – 8 weeks	Novavax Monovalent: 0.5 mL			
		OR Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL			
	2 doses monovalent Novavax	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL			
	1 or more doses of monovalent Novavax	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL			
					OR Novavax Booster* Wait 6 months → Novavax Monovalent: 0.5 mL*	

Per CDC:
“People ages 12 and older who previously received 1 or more doses of Novavax are recommended to receive 1 bivalent mRNA dose.”



*Novavax may only be used as a booster dose in limited situations. Patients must meet ALL of the following criteria to be eligible: 1) 18 years and older 2) completed a primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine, 3) have not received any previous booster dose(s), and 4) are unable (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 months through 4 years)

Date: April 19, 2023



Ages: 6 months thru 4 years									
	COVID-19 Vaccine History								
Pfizer Cap: Maroon Age: 6 mo – 4 years	Unvaccinated		Pfizer Bivalent: 0.2 mL	Wait 3 – 8 weeks	Pfizer Bivalent: 0.2 mL	Wait 8 weeks	Pfizer Bivalent: 0.2 mL	Primary Series Complete	
			<i>OR</i>						
			Moderna Bivalent: 0.25 mL	Wait 4 – 8 weeks	Moderna Bivalent: 0.25 mL	Primary Series Complete			
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older OR Cap: Dark Pink Label: Yellow Age: 6 mo – 5 years	1 dose monovalent Pfizer	Wait 3 – 8 weeks	Pfizer Bivalent: 0.2 mL	Wait 8 weeks	Pfizer Bivalent: 0.2 mL				
	2 doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL						
	3 doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL						
	2 doses monovalent Pfizer and 1 dose <i>bivalent</i> Pfizer		NA						
	1 dose monovalent Moderna	Wait 4 – 8 weeks	Moderna Bivalent: 0.25 mL						
	2 doses monovalent Moderna	Wait 8 weeks	Moderna Bivalent: 0.2 mL						
	2 doses monovalent Moderna and 1 dose <i>bivalent</i> Moderna		NA						

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Administration of Primary Series and Booster Doses (ages 5 years)

Date: April 19, 2023



Ages: 5 years					
COVID-19 Vaccine History					
Pfizer Cap: Orange Age: 5 – 11 years	Unvaccinated		Pfizer Bivalent: 0.2 mL	Primary Series Complete	
			OR		
			Moderna Bivalent: 0.25 mL	Wait 4 – 8 weeks	Moderna Bivalent: 0.25 mL
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older OR Cap: Dark Pink Label: Yellow Age: 6 mo – 5 years	1 dose monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
	1 or more doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
	2 doses monovalent Pfizer and 1 dose bivalent Pfizer		NA		
	Ever received 1 dose bivalent Pfizer (regardless of monovalent vaccine history)		NA		
	1 dose monovalent Moderna	Wait 4 – 8 weeks	Moderna Bivalent: 0.25 mL		
		OR			
		Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
	2 doses monovalent Moderna	Wait 8 weeks	Moderna Bivalent: 0.2 mL		
		OR			
		Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
2 doses monovalent Moderna and 1 dose bivalent Moderna		NA			

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 years through 11 years)

Date: April 19, 2023



Ages: 6 thru 11 years					
		COVID-19 Vaccine History			
Pfizer Cap: Orange Age: 5 – 11 years	Unvaccinated		Pfizer Bivalent: 0.2 mL	Primary Series Complete	
			OR		
			Moderna Bivalent: 0.25 mL	Primary Series Complete	
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older	1 or more doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
			OR		
		Wait 8 weeks	Moderna Bivalent: 0.25 mL		
		2 or more doses monovalent Pfizer and 1 dose <i>bivalent</i> Pfizer		NA	
		Ever received 1 dose <i>bivalent</i> Pfizer (regardless of monovalent vaccine history)		NA	
	1 or more doses monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.2 mL		
			OR		
Wait 8 weeks		Moderna Bivalent: 0.25 mL			
	2 or more doses monovalent Moderna and 1 dose <i>bivalent</i> Moderna		NA		
	Ever received 1 dose <i>bivalent</i> Moderna (regardless of monovalent vaccine history)		NA		

CURRENT RECOMMENDATIONS
(MODERATELY TO SEVERELY IMMUNOCOMPROMISED)

UPDATES – IMMUNOCOMPROMISED

- Immunocompromised people ages 6 years and older are eligible for a second dose of mRNA vaccine.
 - Must be at least 2 months after first dose of bivalent.
- Immunocompromised children ages 6 months thru 4 years...
 - May be eligible for an additional bivalent dose, depending on vaccination history.

Pfizer

Ages 6 months thru 4 years:

- Not currently eligible for any additional bivalent doses due to immunocompromise

Ages 5 years and older:

- One additional dose of bivalent Pfizer at least 2 months after last dose of bivalent mRNA vaccine.

Moderna

Ages 6 months thru 5 years:

- One additional dose of bivalent Moderna at least 1 month after two doses of bivalent Moderna.

Ages 6 years and older:

- One additional dose of bivalent Moderna at least 2 months after last dose of bivalent mRNA vaccine.

COMMON QUESTIONS

QUESTIONS

I have an adult patient who recently received their first dose of a monovalent mRNA vaccine. What do I do now?

- Wait 8 weeks, then administer either bivalent Pfizer or bivalent Moderna.
- There is no preference for which bivalent product to administer, regardless of whether monovalent Pfizer or monovalent Moderna was used as the first dose.

QUESTIONS

Am I still considered “fully vaccinated”, even if I don’t get a booster?

- Yes, you are fully vaccinated even if you haven’t gotten your booster yet.
- The definition of fully vaccinated does not include a COVID-19 booster.
- Fully vaccinated, however, is not the same as having the best protection.
- People are best protected when they stay up to date with COVID-19 vaccinations, which includes getting a booster when eligible.

QUESTIONS

Does the definition “up to date” include boosters?

- Yes.
- You are up to date if you have completed a COVID-19 vaccine primary series and received the most recent booster dose recommended for you by CDC.

Adults and children aged 6 years and older are now considered up to date with COVID-19 vaccines if they got a single dose of bivalent (updated) COVID-19 vaccine.

Children 6 months through 5 years of age who received the Pfizer-BioNTech COVID-19 vaccine are up to date if:

- 6 months to 4 years of age and got at least 3 COVID-19 vaccine doses, including at least one bivalent (updated) COVID-19 vaccine dose.
- 5 years of age and got at least 1 bivalent (updated) COVID-19 vaccine dose.

Children 6 months through 5 years of age who got the Moderna COVID-19 vaccine are up to date if:

- They got at least two Moderna COVID-19 vaccine doses, including at least one bivalent (updated) COVID-19 vaccine dose.

QUESTIONS

Where can I find this information?

- ALL of the recommendations and guidelines will be available on the CDC's website.
 - Direct Link: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- Charts with updated guidelines will be available on the Immunize Arkansas website.
 - Direct Link: <https://www.immunizear.org/covid-19-provider-resources>
- Pfizer EUA: <https://www.fda.gov/media/167211/download>
- Moderna EUA: <https://www.fda.gov/media/167208/download>

RESOURCES

- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/index.html>
- <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines>
- <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines#additional>
- <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines>